Generate Biomedicines, Inc. Common Stock (GENB) — Cash Flow-to-Debt Ratio
Generate Biomedicines, Inc. Common Stock (GENB) has a Cash Flow-to-Debt Ratio of -0.55x as of June 2026, meaning its operating cash flow of $-57.94 Million could theoretically repay -1% of its total liabilities ($105.64 Million) in one year. See Generate Biomedicines, Inc. Common Stock (GENB) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Generate Biomedicines, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Generate Biomedicines, Inc. Common Stock across 2 annual periods. For the full cash flow conversion analysis, see GENB cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Generate Biomedicines, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Generate Biomedicines, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | $-200.62 Million | $953.38 Million | ▼ -70.4% |
| 2024 | -0.12x | $-117.75 Million | $953.35 Million | — |